Saline Inhalation: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

Uses

How to use Saline 0.9 % Solution For Nebulization

This medication is used with a special machine called a nebulizer that changes the solution to a fine mist that you inhale. Learn how to prepare the solution and use the nebulizer properly. If a child is using this medication, a parent or other responsible adult may need to help the child use the nebulizer properly. If you have any questions, ask your doctor, pharmacist, or respiratory therapist.

This product should be clear and colorless. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid.

Using the nebulizer, inhale this medication into your lungs as directed by your doctor. Use this medication only through a nebulizer. Do not swallow or inject the solution. Discard any unused solution. Do not save for future use. To prevent infections, clean the nebulizer and mouthpiece/face mask according to the manufacturer’s directions.

Side Effects

This drug usually has no side effects. If you have any unusual effects, contact your doctor or pharmacist promptly.

Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US –

In the US – Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

In Canada – Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Precautions

Before using sodium chloride solution, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

This solution is safe to use during pregnancy or while breastfeeding when used as directed.

Interactions

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval.

Does Saline 0.9 % Solution For Nebulization interact with other drugs you are taking?

Enter your medication into the WebMD interaction checker

Overdose

If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

Do not share this medication with others.

If you are using this medication on a regular schedule and miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.

Store at room temperature away from light and heat. Do not store in the bathroom. Keep all medications away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

Images

Next

Save up to 80% on your prescriptions.

Available coupons

Save up to 80% on your prescription with WebMDRx

Drug Survey

Have you ever purchased Saline 0.9 % Solution For Nebulization?

Yes, In the past 3 months

Yes, In the past 6 months

Yes, In the past year

Haven’t purchased but considering

Don’t plan to purchase

This survey is being conducted by the WebMD marketing sciences department.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

Today on WebMD

Is nebulized saline a placebo in COPD? | BMC Pulmonary Medicine

• Research article
• Open Access
• Published: 30 September 2004

• Shahina Y Khan¹ &
• B Ronan O’Driscoll¹ 

BMC Pulmonary Medicine
volume 4, Article number: 9 (2004)
Cite this article

• 41k Accesses

• 30 Citations

• 5 Altmetric

• Metrics details

Abstract

Background

Many trials of nebulized therapy have used nebulized saline as a “placebo”. However, nebulized isotonic saline is sometimes used to assist sputum expectoration and relieve breathlessness in COPD patients. We designed this study to establish if nebulized saline had a placebo effect or a clinical effect.

Methods

40 patients were studied following hospital admission for exacerbated COPD (mean FEV1 30% predicted). Patients were randomised to single-blind administration of either 4 mls of nebulized isotonic saline using an efficient nebulizer (active group n = 20) or an inefficient nebulizer (placebo group n = 20). Spirometry and subjective breathlessness scores (Modified Likert Scale) were measured before nebulized treatment and 10 minutes after treatment.

Results

There was no significant change in FEV1 after active or placebo nebulized saline treatment. Patients reported a 4% improvement in mean breathlessness score following placebo (Wilcoxon test; p = 0.37) compared with 23% improvement following active nebulized saline (p = 0. 0001). 65% of patients given active nebulized saline but only 5% of the placebo group reported that mucus expectoration was easier after the treatment.

Conclusions

This study lends support to the current use of nebulized saline to relieve breathlessness (possibly by facilitating sputum clearance) in COPD patients. Lung function was not affected. Nebulized saline can therefore be used as a placebo in bronchodilator studies involving COPD patients but it cannot be used as a placebo in trials assessing symptom relief.

Peer Review reports

Background

Nebulized saline is used by some doctors and physiotherapists to assist mucus clearance and to relieve breathlessness in patients with COPD, bronchiectasis and Cystic Fibrosis. This practice is justified by a small number of studies which have demonstrated enhanced sputum expectoration or improved breathlessness after nebulized saline or humidified oxygen [1–4]. Nebulized hypertonic or isotonic saline has been used to obtain induced sputum specimens from patients with asthma and COPD for diagnostic and experimental purposes [5–9]. For example, Vlachos-Mayer and colleagues [5] used increasing strengths of nebulized saline (from isotonic up to 5%) to induce sputum in 304 patients with asthma and 25 patients with COPD. Satisfactory specimens were obtained in 93% of cases, 17% of asthmatic patients and 56% of COPD patients required only isotonic saline to achieve sputum induction.

However, nebulized saline has also been used as a placebo in several trials involving nebulized bronchodilator therapy [10, 11]. For example, Jenkins et al [10] found in a double blind study that patients reported clinical benefit from nebulized saline (with MDI bronchodilator therapy) which was similar to the subjective response to nebulized bronchodilator therapy given with placebo MDI therapy. It was assumed that these patients had a placebo response to nebulized saline but it is also possible that they may have experienced a non-bronchodilator benefit from nebulized saline. We have designed a trial to determine whether the symptomatic benefit associated with nebulized saline use in clinical trials is a placebo effect or a non-bronchodilator therapeutic effect.

Methods

40 patients were studied during a hospital admission for an exacerbation of COPD. Patients were recruited at a time when their condition had stabilized prior to their planned discharge from hospital. Clinical details of the patients are summarised in table 1. Six patients undertook both limbs of the study (partial crossover design).

Table 1 Patient Characteristics

Full size table

Patients were randomised to receive 4 mls of 0.9% saline using an efficient nebulizer system (active group) or an inefficient nebulizer system (placebo group). The active nebulizer was a System 22 Acorn nebulizer (Medic-Aid, Bognor Regis UK Ltd) driven by the hospital’s piped oxygen supply at a flow rate of 9 l/min for 10 minutes. This nebulizer system was found to deliver 95% of particles in the size range 2. 5 to 2.8 microns using a Malvern laser system. (Measurement courtesy of Dr Steve Newman, Principal Physicist, Royal Free Hospital, London, UK). This small particle size was selected to achieve effective delivery to the airways. The placebo nebulizer was an old model (1980s) Bard Inspiron nebulizer (no longer manufactured) driven by oxygen at a flow rate of 3 l/min. This nebulizer system delivered 95% of particles in the size range 9.5 to 9.9 microns. This particle size was selected to achieve a placebo effect with deposition in the tubing of the system and in the pharynx but little penetration to the airways [12]. Both nebulized treatments were administered by mouthpiece to avoid nasal deposition of saline droplets and to make it less likely that patients would notice that the output from the placebo system was different to previous nebulized treatment which they had received.

The trial was conducted in a single-blind manner. 40 slips of paper were labelled “Treatment A” or “Treatment B” and placed in opaque brown envelopes. These were shuffled in random order and each patient was asked to select one envelope. This was then opened by the investigator and the appropriate treatment was administered (A active, B Placebo). For the six patients who took part in the study twice, the second treatment consisted of whichever treatment they had not received previously.

Patients were told that we wished “to observe the effects of a nebulized treatment which is not a new or experimental drug”. They were not informed of the exact nature of the nebulized treatments as this might have led patients to try to guess if the treatment which they received was a “placebo”. The Ethics Committee agreed that it would not have been possible to measure a true placebo effect if patients were made aware that both treatments were saline (not a bronchodilator) and one of the nebulizers was deliberately made to run inefficiently.

Patients were recruited on the Respiratory Wards of a University hospital. We recruited patients who had diagnosis of COPD confirmed by a respiratory consultant (patients with asthma or bronchiectasis were excluded from the study). Patients were approached by one of the investigators whilst in a relatively stable phase prior to discharge from hospital following an admission for exacerbated COPD. All testing was undertaken between 12.00 and 16.00, at least four hours after bronchodilator treatment.

Prior to participating in the study, patients gave informed consent and undertook baseline measurement of FEV1 and FVC using the best of 3 blows on a Microlab 3300 Spirometer (Micro-Medical LTD, Rochester, UK. Peak Expiratory Flow (PEF) was measured using a Wright’s Peak Flow meter. Each patient also recorded an assessment of their perceived level of breathlessness using a seven point modified Likert scale (1 = Not breathless, 2 = Very mild breathlessness, 3 = Mild breathlessness, 4 = Moderate breathlessness, 5 = Severe breathlessness, 6 = Very severe breathlessness, 7 = Worst possible breathlessness).

Ten minutes after completion of nebulized therapy, FEV1, FVC and PEF measurements and subjective breathlessness scores were repeated. Patients also recorded a subjective assessment of benefit using the following modified Likert scale. (1 = No benefit from this treatment, 2 = Very slight benefit, 3 = Slight benefit, 4 = Moderate benefit, 5 = Good benefit,, 6 = Very good benefit, 7 = Best possible benefit).

Patients then received 4 puffs of salbutamol (400 mcg) using a Metered Dose Inhaler and 750 ml Volumatic spacer (Glaxo Smith Kleine UK).

Fifteen minutes later, FEV1, FVC and PFR measurements and subjective breathlessness scores and symptom relief scores were repeated.

All data was entered on a SPSS version 9 statistical package. Mann Whitney U-test was used to compare lung function tests and symptom relief scores. Wilcoxon Signed Rank test was used to compare the change in breathlessness scores for matched pairs before and after nebulized saline.

The study was approved by Salford and Trafford Research Ethics Committee. All patients gave written informed consent to partake in the study and to receive a single dose of nebulized treatment (in addition to all usual treatment).

Results

34 patients completed the study; patient details are summarised in table 1. 6 patients took part in the study twice (once in each limb). This allowed 20 treatments with each nebulizer system to be compared.

The baseline FEV1 of the two treatment groups was well matched. Both groups had a non-significant fall in FEV1 after nebulized saline therapy and a small rise in FEV1 after 400 mcg salbutamol from MDI-spacer (Table 2). FVC, and PEF changes (not shown in table) were similar to FEV1 changes.

Table 2 Results All results expressed as Medians in top line and Mean (and 95% CI) in second line.

Full size table

The placebo group had a 4% improvement in breathlessness after treatment (Wilcoxon p = 0.37) compared with a 23% improvement after active nebulized saline (Wilcoxon p = 0.0001). This corresponded to a reduction from 4/7 (moderate breathlessness) before treatment to 3/7 (mild breathlessness) after treatment in the active treatment group.

The mean symptom relief score (patient’s assessment of benefit) for the active treatment was 3/7, (slight benefit) almost identical to the response to 400 mcg salbutamol from MDI. The placebo group had a score of 2/7(very slight benefit) after nebulized placebo and 3/7(Slight benefit) after 400 mcg salbutamol from MDI.

15 patients in the active group felt better after nebulized saline, 5 felt the same and no patient felt worse. Six patients in the placebo group felt better after nebulized treatment, 12 felt the same and 2 felt worse (Chi Squared test p = 0.013).

Patients were asked if the nebulized treatments had any effect other than relief of breathlessness. 13 patients in the active group (65%) said that the nebulized treatment assisted sputum expectoration. Only 1 patient in the placebo group reported this effect (Difference between groups: -Fisher exact test, p = 0.0001). No patient reported any adverse effects from either nebulized treatment.

Discussion

This is the first study which has compared active nebulized saline with placebo nebulized saline. The results suggest that nebulized saline has non-bronchodilator therapeutic effects that are possibly explained by airway-moistening and sputum-inducing effects of nebulized saline. Sputum volume was not measured in the present study but two thirds of patients who were given nebulized saline through an efficient nebulizer system reported that it helped them to expectorate sputum. This finding is consistent with the results of previous studies which have shown improved sputum clearance and decreased breathlessness following the open administration of nebulized saline [1, 3] The results of the present study may be explained by airway-moistening and sputum-inducing effects of nebulized saline, both isotonic and hypertonic [1–9] The study of Vlachos-Mayer and colleagues [5] showed that most asthmatic patients required hypertonic saline to achieve sputum induction but more than half of COPD patients achieved sputum induction with nebulized isotonic saline (similar to the finding that 65% of COPD patients in the present study reported enhanced sputum clearance following nebulized saline).

Previous studies have shown that nebulized saline can have a bronchoconstrictor effect in some patients which is greater with hypertonic saline than with isotonic saline and greater in asthma patients than COPD patients [5, 6, 8, 9] Nebulized isotonic saline had no significant effect on FEV1 in the study of Poole et al [3] or in the present study.

The main strength of the present study is inclusion of a placebo limb using an inefficient nebulizer system. Patients in the placebo group believed that they were receiving a nebulized treatment because a placebo effect could have been abolished if patients were told that both treatments involved no active medication and one of the patients involved an inefficient nebulizer system. This issue was discussed fully with the ethics committee and found to be acceptable because the patients did not miss any of their regular medication and they did not receive any pharmacological treatment. The use of a mouthpiece ensured that patients could not see or feel that the output from the experimental system was different to the nebulized bronchodilator therapy which they had received during their hospital admission (usually via a facemask). Furthermore, only 6 patients took part in both limbs of the study so most patients could not have tried to guess which treatment was more effective.

The 23% improvement in breathlessness in the active group was equivalent to the subjective benefit following 400 mcg of salbutamol from MDI-spacer. This improvement in breathlessness occurred without bronchodilation, mirroring the findings of Poole et al [3]. Based on the patients’ observations and the results of previous studies, we believe that the therapeutic effect of nebulized saline may be produced by enhanced sputum clearance. A previous study at this hospital showed a similar subjective response to nebulized saline (given at 7 am) but the previous study also reported an improvement in FEV1 and PEF [13]. Patients in the previous study received nebulized saline on awakening, prior to their first bronchodilator treatment of he day. In these circumstances, it is likely that the nebulized saline assisted the expectoration of copious overnight secretions in the airways with some subsequent improvement in airflow. Patients in the present study were treated at about mid-day, having had bronchodilator therapy on awakening. It is therefore not surprising that the beneficial effects of nebulized saline were more modest in the present study. However, this study lends support to the common clinical practice of allowing patients with COPD to have nebulized saline “as required” as a supplement to regular nebulized bronchodilator therapy. This may assists sputum expectoration and relieve breathlessness without the side-effects that would occur if additional beta agonist treatment were given.

This study is in agreement with previous studies which have shown no bronchodilator effect (or a small bronchoconstrictor effect) when nebulized saline is given to patients with COPD [3]. This justifies the continuing use of nebulized saline as a placebo treatment in clinical trials of bronchodilator therapy which measure rise in FEV1 or PEF as the primary outcome measure.

However, as nebulized saline has non-bronchodilator therapeutic effects, it cannot be used as an inert placebo treatment in clinical studies where breathlessness or quality of life are to be measured. For example, Jenkins et al concluded that nebulized treatment had a strong placebo effect because patients expressed a preference for nebulized treatment even though the same bronchodilator effect could be achieved for most of their patients when nebulized saline was given with active bronchodilator therapy from a MDI device [10]. It is likely that many of these patients experienced a non-bronchodilator therapeutic benefit such as enhanced mucus clearance during nebulized saline therapy. It would be possible to co-administer nebulized saline with MDI bronchodilator therapy as an alternative to nebulized bronchodilator therapy for some patients with COPD who report difficulties with mucus clearance. However, this would be more inconvenient than nebulized bronchodilator therapy (and at least as expensive). For future clinical trials it would be possible to have two control groups, one receiving nebulized saline using an efficient system and one group using an inefficient system such as that used in the present study. This would allow investigators to assess whether nebulized saline had any therapeutic effect on their patients and it would also assess the true placebo response rate.

British and European nebulizer guidelines state that most patients with airflow obstruction should be treated with hand-held devices unless they have demonstrated clear additional benefit from the use of nebulized treatment in carefully monitored domiciliary studies [12, 14]. The present study supports these recommendations, especially the provision that some patients may be commenced on nebulized treatment on the basis of substantial subjective benefit even if an additional bronchodilator response cannot be demonstrated. This study also supports the present practice of many physiotherapists and doctors who use nebulized isotonic saline to assist sputum clearance for patients with COPD who have difficulty in expectorating sputum.

Abbreviations

FEV1:

Forced Expiratory Volume in 1 second

FVC:

Forced Vital Capacity

PEF:

Peak Expiratory Flow

COPD:

Chronic Obstructive Pulmonary Disease

MDI:

Metered dose inhaler

References

1. “>

   Sutton PP, Gemmell HG, Innes N, Davidson J, Smith FW, Legge JS, Friend JA: Use of nebulized saline and nebulized terbutaline as an adjunct to chest physiotherapy. Thorax. 1988, 43: 57-60.

   Article 
   CAS 
   PubMed 
   PubMed Central 

   Google Scholar 

2. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Cobertson CF: Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Paediatr Pulmonol. 1996, 21: 77-83. 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.3.CO;2-R.

   Article 
   CAS 

   Google Scholar 

3. Poole PJ, Brodie SM, Stewart JM, Black PN: The effects of nebulized isotonic saline and terbutaline on breathlessness in severe chronic obstructive pulmonary disease (COPD). Aust NZ J Med. 1998, 28: 322-326.

   Article 
   CAS 

   Google Scholar 

4. “>

   Conway JH, Fleming JS, Perring S, Holgate ST: Humidification as an adjunct to chest physiotherapy in aiding tracheo-bronchial clearance in patients with bronchiectasis. Respir Med. 1992, 86: 109-114.

   Article 
   CAS 
   PubMed 

   Google Scholar 

5. Vlachos-Mayer H, Leigh R, Sharon RF, Hussack P, Hargreave FE: Success and safety of sputum induction in the clinical setting. Eur Respir J. 2000, 16: 997-1000. 10.1183/09031936.00.16599700.

   Article 
   CAS 
   PubMed 

   Google Scholar 

6. Rytila PH, Lindqvist AE, Laitinen LA: Safety of sputum induction in chronic obstructive pulmonary disease. Eur Respir J. 2000, 15: 1116-1119. 10.1034/j.1399-3003.2000.01522.x.

   Article 
   CAS 
   PubMed 

   Google Scholar 

7. Wark AB, Simpson JL, Hensley MJ, Gibson PG: Safety of sputum induction with isotonic saline in adults with acute severe asthma. Clin Exp Allergy. 2001, 31: 1745-1753. 10.1046/j.1365-2222.2001.01230.x.

   Article 
   CAS 
   PubMed 

   Google Scholar 

8. Sutherland ER, Pak J, Langmack EL, Silkoff PE, Martin RJ: Safety of sputum induction in moderate-to-severe chronic obstructive pulmonary disease. Respiratory Medicine. 2002, 96: 482-486. 10.1053/rmed.2002.1342.

   Article 
   PubMed 

   Google Scholar 

9. Cataldo D, Foidart JM, Lau L, Bartsch P, Djukanovic R, Louis R: Induced Sputum: Comparison between isotonic and hypertonic saline solutions in patients with asthma. Chest. 2001, 120: 1815-1821. 10.1378/chest.120.6.1815.

   Article 
   CAS 
   PubMed 

   Google Scholar 

10. Jenkins SC, Heaton RW, Fulton TJ, Moxham J: Comparison of domiciliary nebulized salbutamol and salbutamol from a metered dose inhaler in stable chronic airflow limitation. Chest. 1987, 91: 804-07.

    Article 
    CAS 
    PubMed 

    Google Scholar 

11. Goldman JM, Teale C, Muers MF: Simplifying the assessment of patients with chronic airflow limitation for home nebulizer therapy. Respiratory Medicine. 1992, 86: 33-38.

    Article 
    CAS 
    PubMed 

    Google Scholar 

12. Boe J, Dennis JH, O’Driscoll BR: European Respiratory Society Guidelines on the use of nebulizers. European Respiratory Journal. 2001, 18: 228-242. 10.1183/09031936.01.00220001.

    Article 
    CAS 
    PubMed 

    Google Scholar 

13. O’Driscoll BR, Kay EA, Taylor RJ, Bernstein A: Home nebulizers: can optimal therapy be predicted by laboratory studies?. Respiratory Medicine. 1990, 84: 471-477.

    Article 
    PubMed 

    Google Scholar 

14. “>

    O’Driscoll BR: Nebulizers for chronic obstructive pulmonary disease. Thorax. 1997, 52 (Suppl 2): S49-52.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

Pre-publication history

• The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/4/9/prepub

Download references

Acknowledgements

The authors would like to thank Dr Steve Newman of the Royal Free Hospital, London, UK for testing the two nebulizer systems used in the trial.

Author information

Authors and Affiliations

1. Dept of Respiratory Medicine, Hope Hospital, Salford, M6 8HD, UK

   Shahina Y Khan & B Ronan O’Driscoll

Authors

1. Shahina Y Khan

   View author publications

   You can also search for this author in
   PubMed Google Scholar

2. B Ronan O’Driscoll

   View author publications

   You can also search for this author in
   PubMed Google Scholar

Corresponding author

Correspondence to
B Ronan O’Driscoll.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

BROD developed the concept for the study and both authors designed the study protocol.

SYK recruited patients and performed all study measurements.

Both authors assisted in analysis of the data and preparation of the manuscript.

Rights and permissions

Reprints and Permissions

About this article

Is hypertonic sodium chloride inhalation through a nebulizer an effective and safe treatment for young children with acute bronchiolitis?

This translation is out of date. Please click here for the latest English version of this review.

Survey question

Is hypertonic sodium chloride inhalation through a nebulizer safe and effective treatment for young children with acute bronchiolitis compared with saline?

Relevance

Acute viral bronchiolitis is the most common lower respiratory tract infection in children under two years of age. Bronchiolitis occurs when small structures (bronchioles) leading to the lungs become infected, causing inflammation, swelling, and phlegm production. This makes breathing difficult, especially in very young children, and is accompanied by coughing and wheezing/wheezing.

Since bronchiolitis usually results from a viral infection, drug treatment is often ineffective. Hypertonic sodium chloride solution (sterile salt water solution), which is infused into the body through a nebulizer, can help relieve breathing problems.

We compared the use of hypertonic (≥ 3%) saline with normal (0.9%) saline in children with acute bronchiolitis.

This review is an update of a previous review published in 2008, 2010 and 2013.

Search date

August 11, 2017.

Study profile

We identified 26 new studies to update this review, of which 9are awaiting evaluation and another 17 (with 3105 participants) have been added. A total of 28 trials were conducted, in which 4195 children with acute bronchiolitis took part.

Main results

The use of hypertonic saline via a nebulizer may shorten hospital stay by 10 hours compared to normal saline in children hospitalized with acute bronchiolitis. We found that scores on the ‘Clinical Severity Scale’, which is used by physicians to assess the health of patients, improved with the use of hypertonic saline (via a nebulizer) compared with normal (physiological) saline in children receiving outpatient or inpatient care. Hypertonic saline inhalation through a nebulizer can also reduce the risk of hospitalization by 14% in children receiving care in an outpatient setting or in the emergency department. We found only minor and self-limiting adverse effects when using hypertonic saline (via a nebulizer) along with medications to relax the airways (bronchodilators).

The reduction in hospital stays was less than previously thought. However, the duration of hospital stay of children was reduced by an average of 10 hours, and this result is significant, since bronchiolitis is usually of short duration. Hypertonic saline (via a nebulizer) has proven to be a safe treatment, inexpensive, and widely available.

Quality of evidence

We rated the quality of the evidence from low to moderate: there was inconsistency between trial results and there was a risk of bias in some trials. Therefore, further large trials are needed to confirm the benefit of hypertonic saline (via a nebulizer) in children with bronchiolitis treated as outpatients or inpatients.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.

Donate

Translation notes:

Translation: Morozov Nikita Sergeevich. Editing: Prosyukova Ksenia Olegovna, Yudina Ekaterina Viktorovna. Project coordination for translation into Russian: Cochrane Russia – Cochrane Russia on the basis of the Russian Medical Academy of Continuing Professional Education (RMANPE). For questions related to this transfer, please contact: [email protected]

Miramistin for inhalation with a nebulizer: an effective treatment procedure

Contents

• 1 Miramistin for inhalation with a nebulizer
  • for inhalation
  • 1.3 Indications for inhalation with Miramistin
  • 1.4 Features of using Miramistin for inhalation
  • 1.5 Dosage and frequency of inhalation
  • 1.6 Contraindications to the use of Miramistin for inhalation
  • 1.7 Adverse reactions with Miramistin inhalation
  • 1.8 How to properly inhale Miramistin
  • 1.9 Features of long-term use of Miramistin for inhalation
  • 1.10 Importance of consulting a doctor before using Miramistin

  900 61 1.11 Related videos:

  • 1.12 Q&A:
    • • 1. 12.0.1 How is Miramistin for inhalation treated?
      • 1.12.0.2 What dosage should be used for Miramistin inhalation?
      • 1.12.0.3 How often should Miramistin be inhaled?
      • 1.12.0.4 What are the advantages of using Miramistin for inhalation?

Miramistin for inhalation with a nebulizer is an effective remedy for the treatment of respiratory infections and inflammatory diseases of the throat and nose. Learn about the benefits and rules for using Miramistin as an inhalation solution using a nebulizer.

Miramistin is an innovative drug that has proven its effectiveness in the fight against various infectious diseases. In particular, Miramistin can be used for inhalation with a nebulizer, which makes it possible to achieve maximum treatment efficiency.

If you suffer from diseases of the upper and lower respiratory tract, inhalations of Miramistin using a nebulizer are one of the most effective methods of treatment. Miramistin penetrates into the most remote areas of the lungs and acts directly on pathogenic microorganisms, destroying them and preventing the development of infection.

Benefits of Miramistin inhalation using a nebulizer:

• Rapid and effective drug action;
• Penetration of miramistin into the most inaccessible parts of the respiratory system;
• Providing anti-inflammatory, anti-allergic and antimicrobial action;
• Increase local immunity;
• No systemic effect on the body;
• Safe and easy to use.

Miramistin inhalations with a nebulizer can be used to treat diseases such as rhinitis, sinusitis, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia and others. Miramistin eliminates the symptoms of the disease, improves the condition of the respiratory system and promotes rapid recovery.

Trust your health to professionals and choose Miramistin inhalations with a nebulizer. This effective treatment procedure will help you quickly cope with the infection and return to a full life without restrictions and discomfort.

Benefits of nebulizer inhalation

1. Effective treatment of mild diseases: Miramistin nebulizer inhalation delivers the drug directly to the respiratory tract. It helps fight infection effectively and also relieves symptoms of illnesses such as asthma, bronchitis, and chronic obstructive pulmonary disease.

2. Safety and ease of use: Inhalation with a nebulizer allows you to accurately dose the medicine, which reduces the risk of side effects. The procedure also causes no discomfort, making it convenient for children and patients with poor health.

3. Speed ​​of action: When using a nebulizer, the drug instantly enters the respiratory system and begins to act faster than when taking drugs inside. This greatly speeds up the treatment process and facilitates the patient’s condition.

4. Possibility of choosing a drug: Nebulizer inhalation allows the use of various drugs depending on the cause of the disease. This allows you to most effectively treat different types of infections and restore the function of the respiratory system.

5. Ease of use: The nebulizer inhalation procedure does not require special skills or special equipment. It is enough to follow the instructions and mix the medicinal substance with saline correctly. This makes inhalation available to all patients.

Mechanism of action of Miramistin inhalation

Miramistin is a unique drug that shows high efficiency when inhaled using a nebulizer. The main mechanism of action of Miramistin is its antimicrobial effect, which can neutralize various types of bacteria, fungi and viruses.

A feature of Miramistin is its ability to quickly penetrate into the affected tissues and mucous membranes, forming a protective barrier against harmful microbes and infections. This allows you to suppress inflammation and quickly restore the health of the respiratory system.

Miramistin inhalations are indicated for various respiratory infections, including acute respiratory viral infections, sinusitis and frontal sinusitis.

Miramistin inhalation indications

Miramistin is a powerful antiseptic that is widely used for the treatment and prevention of various diseases of the respiratory system. Miramistin inhalations are recommended for the following indications:

1. Acute respiratory infections. Inhalations will help to cope with a runny nose, cough, sore throat and prevent the progression of the infection.
2. Chronic bronchitis and obstructive pulmonary disease. Miramistin improves sputum discharge, reduces inflammation and heals the mucous membrane of the respiratory tract.
3. Pneumonia and pleurisy. Miramistin inhalations will help eliminate the causative agent of infection, reduce inflammation and speed up the healing process.
4. Allergic rhinitis and asthma. Miramistin is able to alleviate the symptoms of allergic reactions and ease breathing in patients with asthma.

Miramistin for inhalation is a safe and effective drug that is recommended for use in these diseases. However, before use, it is necessary to consult a doctor in order to receive individual recommendations on dosage and frequency of the procedure.

Features of the use of Miramistin for inhalation

Miramistin is an effective and safe medicine that is widely used for inhalation. Its unique action allows you to effectively fight inflammation and infection in the respiratory tract.

The advantage of Miramistin for inhalation is its local action, which allows to achieve the best effect in the treatment of diseases of the upper and lower respiratory tract. It penetrates into the most inaccessible parts of the respiratory system, providing high-quality washing and disinfection.

No special equipment is required to use Miramistin for inhalation. The medicine is packaged in a convenient bottle or bubble with a spray, which facilitates the inhalation process. The procedure is carried out 1-2 times a day, usually for 5-7 days.

Miramistin for inhalation demonstrates high safety in use. It does not cause allergic reactions and side effects, so it can be used even in children and people with sensitive skin. Due to its properties, Miramistin for inhalation is an integral component of the treatment of diseases of the respiratory system.

Dosage and frequency of inhalations

To achieve the maximum effect from inhalations using Miramistin, it is recommended to follow a certain dosage and frequency of the procedure.

For patients over 12 years of age and adults, the dosage is 4-5 ml diluted 1:1 with saline. Inhalations are carried out 2-3 times a day.

In children aged 3 to 12 years, the dosage is 2-3 ml diluted with saline in a ratio of 1:2. The frequency of inhalations is 2 times a day.

For children under 3 years of age, the dosage and frequency of inhalations are determined by the attending physician, based on the age and condition of the child.

It is important to remember that failure to comply with the recommended dosage and frequency of inhalation may reduce the effectiveness of treatment. Before starting treatment, it is necessary to consult a doctor and strictly follow his prescription.

Contraindications for the use of Miramistin for inhalation

Miramistin is an effective antimicrobial agent, but there are several circumstances in which its use for inhalation is not recommended.

1. Individual intolerance: If you have experienced allergic reactions to Miramistin before, it is better to refrain from using it for inhalation. In this case, consult your doctor about other possible treatments.

2. Pregnancy and lactation: Do not inhale with Miramistin if you are pregnant or breastfeeding. Such decisions must be made by the doctor, who will suggest alternative treatments that are safe for you and the baby.

3. Acute diseases of the upper respiratory tract: In cases of acute inflammation accompanied by high fever and profuse runny nose, Miramistin inhalations may be ineffective and even aggravate the symptoms of the disease. In this case, it is proposed to postpone their implementation until the time when the state of health stabilizes again.

4. Children’s age: For children under 3 years of age Miramistin inhalations are not recommended without a doctor’s prescription. Age-related features of the body and a lower dosage require a special approach and supervision by a specialist.

5. No medical prescription: Consult your doctor before using Miramistin for inhalation. Only he can determine whether you should carry out such procedures and at what dosage they will be most effective and safe.

Miramistin Inhalation Adverse Reactions

Miramistin is an effective antimicrobial drug that is widely used for inhalation by nebulizer for upper respiratory diseases. However, like any drug, it may cause some adverse reactions in patients.

Secondly, some patients may experience an unpleasant sensation of bitterness or burning when inhaled with Miramistin. This is due to its specific taste and smell. In this case, it is recommended to carry out inhalations through a nebulizer in order to avoid direct contact of Miramistin with the mucous membrane of the mouth and throat.

In addition, some patients may experience side effects after Miramistin inhalation, such as headache, dry mouth or runny nose. If these symptoms persist or worsen, a doctor should be consulted to adjust the dosage or possibly change the drug.

In general, Miramistin inhalations are an effective treatment procedure, however, it is necessary to be aware of the possibility of adverse reactions and carefully monitor the state of health during this procedure.

If you have any unpleasant symptoms or doubts about Miramistin inhalation, be sure to consult your doctor to get a professional assessment and recommendations for further treatment.

How to carry out Miramistin inhalations correctly

Miramistin inhalations are an effective procedure for the treatment of various diseases of the upper respiratory tract. They allow you to deliver the medicinal substance directly to the lungs, providing a quick and effective effect on the problem area.

Starting inhalation, it is necessary to take a comfortable position, sitting or lying down. It is recommended to first clear the nasal passages of mucus with saline or other suitable preparations. Then you should saturate the oral cavity with Miramistin and begin to inhale and exhale through the nebulizer, while trying to completely fill the lungs with an aerosol.

The duration of Miramistin inhalations can vary from a few minutes to 20-30 minutes, depending on the adjustment of the nebulizer and the doctor’s recommendations. After the procedure, it is recommended not to eat or drink for 30 minutes to ensure the maximum effect of the medicine.

It is important to remember that Miramistin inhalations should be carried out strictly according to the doctor’s prescription. Self-medication can be dangerous and ineffective. Before starting treatment, you should consult with a specialist and read the instructions for the drug in detail.

Features of long-term use of Miramistin for inhalation

Miramistin is an effective antiseptic drug that is widely used in medicine for the treatment and prevention of various infectious diseases. It has powerful antimicrobial and anti-inflammatory properties, making it ideal for inhalation.

It is important to note that Miramistin is perfectly compatible with other medicines and does not interact with them, which makes it possible to use it in complex therapy. In addition, the drug does not cause allergic reactions and is indicated for use even in the presence of an allergic reaction to other drugs.

Long-term use of Miramistin for inhalation allows to achieve a stable therapeutic effect. The drug has a long-lasting effect, which reduces the number of inhalations per day and simplifies the treatment process. Due to this, Miramistin is the optimal choice for patients who require long-term inhalation therapy.

• Strong antimicrobial activity
• Safe and non-addictive
• Good drug compatibility
• Absence of allergic reactions
• Stable therapeutic effect

Importance of consulting a doctor before using Miramistin

Miramistin is an effective drug for inhalation with a nebulizer, which is widely used in the treatment of various diseases of the upper respiratory tract. However, before using this drug, it is important to consult a specialist – a doctor.

Consulting a doctor before using Miramistin will allow you to determine the correct dosage and regimen of the drug, taking into account the individual characteristics of the patient. The doctor can also evaluate the indications and contraindications for the use of Miramistin in order to avoid possible unpleasant or harmful consequences.

A pulmonologist or otorhinolaryngologist can help determine if you need to use Miramistin for inhalation with a nebulizer and which treatment will be most effective in your particular case. In addition, a doctor’s consultation will give you answers to all your questions and help you avoid possible errors in the use of the drug.

Do not self-medicate and start using Miramistin without consulting a doctor. Only a specialist will be able to determine the optimal dosage and regimen for the use of the drug, based on your state of health and the characteristics of the disease.

The importance of consulting a doctor before using Miramistin should not be underestimated. Health is the most valuable thing, and only a professional can help you choose the most effective and safe treatment.

Related videos:

Q&A:

How is Miramistin for inhalation treated?

Miramistin for inhalation is used with a nebulizer that turns the drug into an aerosol. The aerosol enters the respiratory tract, penetrates the lungs and has an antimicrobial effect on the mucous membranes, destroying pathogenic microorganisms. Thus, there is a treatment of infectious diseases of the respiratory system.

What dosage should be used for Miramistin inhalation?

The dosage of Miramistin for inhalation should be selected depending on the age of the patient. For adults and children over 12 years of age, it is recommended to use 4 ml of a 0.01% Miramistin solution. Children from 3 to 12 years old should use 2 ml of solution, and children under 3 years old – 1 ml of solution.

How often should Miramistin be inhaled?

The frequency of Miramistin inhalations depends on the severity and nature of the disease. On average, it is recommended to carry out inhalations 2-3 times a day. However, for an accurate recommendation on the frequency of inhalation, you should consult a doctor.

What are the advantages of using Miramistin for inhalation?

The use of Miramistin for inhalation has several advantages. Firstly, Miramistin has a wide spectrum of antimicrobial activity and acts on most pathogenic microorganisms, including viruses and fungi. Secondly, Miramistin inhalations allow the drug to be delivered directly to the inflamed mucous membranes of the respiratory system, which increases its effectiveness. Finally, Miramistin does not cause irritation of the mucous membranes and has no side effects.